Compare Inovio Pharmaceuticals Inc (INO) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Las Vegas Sands Corp. — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Las Vegas Sands Corp. trades at $45.98 (market cap $29.44B). The key difference: Las Vegas Sands Corp. is far larger — about 374.8× Inovio Pharmaceuticals Inc's market cap, and Las Vegas Sands Corp. pays a 2.64% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | LVS | |
|---|---|---|
Market Cap | $78.55M | $29.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $69.49 |
52-Week Low | $0.66 | $44.78 |
Enterprise Value | $49.56M | $41.33B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
LVS trades at $45.75, up 0.64% over the past 24 hours, with a bearish technical signal but strong fundamentals including a P/E of 17.62 and net income margin of 12.59%. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company maintains robust cash flow from operations at $3.02 billion in 2025 and has announced a $0.30 dividend for H2 2026, reflecting financial stability.
The outlook for LVS is cautiously optimistic, supported by analyst consensus price target of $60.75 and 59% buy ratings. Key opportunities include revenue growth and ESG achievements, while risks involve high debt levels and competitive pressures in the gaming sector. Investors should weigh solid profitability against macroeconomic and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
